Ezetimibe + simvastatin (Merck/Schering-Plough)

Current Opinion in Investigational Drugs

Volumn 5, Issue 9, 2004, Pages 984-992

  Flores, Nicholas A ^a  

^a Ipswich   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE SIMVASTATIN COMBINATION; EZETIMIBE-SIMVASTATIN COMBINATION; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HUMAN; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; HUMANS; HYPERCHOLESTEROLEMIA; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 16644395416     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. 199761 Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease - The Scandinavian Simvastatin Survival Study (4S). Pederson TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG et al LANCET 1994 344 8934 1383-1389
2. 272692 In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. VanHeek M, France CF, Compton DS, McLeod HL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR J PHARMACOL EXP THER 1997 283 1 157-163
3. 349378 A novel one-step diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors. Wu G, Wong Y, Chen X, Ding Z J ORG CHEM 1999 64 10 3714-3718
4. 368021 Merck and SP enter development agreements. Merck & Co Inc PRESS RELEASE 2000 May 23
5. 417419 Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR DIABETES 2001 50 6 1330-1335
6. 417424 The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Van Heek M, Compton DS, Davis HR EUR J PHARMACOL 2001 415 1 79-84
7. 434252 Merck and Schering-Plough expand partnership worldwide to develop and market new cholesterol medicines. Merck & Co Inc PRESS RELEASE 2001 December 19
8. 450565 Zetia boosts statin therapy in HoFH patients. Merck & Co Inc, Schering-Plough Corp PRESS RELEASE 2002 May 07
9. 466305 The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor in dogs. Davis HR, Pula KK, Alton KB, Burrier RE, Watkins RW METABOLISM 2001 50 10 1234-1241
10. 467129 Products in development: Product pipeline: Worldwide ethical products/September 2002. Schering-Plough Corp COMPANY WORLD WIDE WEB SITE 2002 September 27
11. 481035 Ezetrol (ezetimibe) ready for approval in the European Union. Merck & Co Inc, Schering Plough Corp PRESS RELEASE 2003 March 06
12. 481539 HDL Cholesterol 2003 - The Knowledge Foundation's fourth annual international conference, metabolic pathways and drug targets, Cambridge, MA, USA. Meng CQ IDDB MEETING REPORT 2003 March 2-4
13. 513627 Merck/Schering-Plough Pharmaceuticals announces submission of new drug application to FDA for ezetimibe/simvastatin tablet, an investigational cholesterol-lowering medicine. Schering-Plough Corp, Merck & Co Inc PRESS RELEASE 2003 November 17
14. 513822 Schering-Plough analysts & portfolio managers meeting. Schering-Plough Corp COMPANY PRESENTATION 2003 November 18
15. 513865 Biochemical safety and efficacy of co-administration of ezetimibe and simvastatin among patients with chronic kidney disease: The second UK heart and renal protection. Landray MJ, Baigent C, Leaper C CIRCULATION 2003 108 17 Abs 3325
16. 514507 The effects of ezetimibe co-administered with simvastatin on C-reactive protein from a large cohort of hypercholesterolemic patients. Sager P, Capece R, Lipka L, Strony J, Yang B, Suresh R, Mitchel Y, Veltri E CIRCULATION 2003 108 17 Abs 1459
17. 527216 Pfizer Inc: Annual Report 2003. Pfizer Inc ANNUAL REPORT 2004 February 26
18. 528123 Merck and Schering-Plough announce first global marketing approval of ezetimibe/simvastatin tablet in Mexico for treatment of elevated cholesterol levels. Merck & Co Inc PRESS RELEASE 2004 March 19
19. 528692 The American College of Cardiology - 53rd Annual Scientific Session, New Orleans, LA, USA, 7-10 March. Susman E IDDB MEETING REPORT 2004 March 7-10
20. 530395 Merck and Schering-Plough's ezetimibe + simvastatin product approved in Germany. Merck & Co Inc, Schering-Plough Corp PRESS RELEASE 2004 April 02
21. 531878 Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E AM J CARDIOL 2003 92 12 1414-1418
22. 531879 Combined lipid lowering drug therapy for the effective treatment of hypercholesterolaemia. Shepherd J EUR HEART J 2003 24 8 685-689
23. 531880 Ezetimibe: A first-in-class, novel cholesterol absorption inhibitor. Lipka LJ CARDIOVASC DRUG REV 2003 21 4 293-312
24. 531881 Co-administration of ezetimibe with simvastatin. Dobs AS, Guyton JR, McClusky D, Ponsonnet D, Melani L, Lebeaut A, Yang B, Veltri E J AM COL CARDIOL 2003 41 6 Suppl A 227A
25. 531882 Efficacy and safety of ezetimibe co-administered with statins in elderly patients with hypercholesterolemia. Melani L, Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E J AM GERIATR SOC 2003 51 4 Suppl S85
26. 531883 Ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP J AM COLL CARDIOL 2002 40 12 2125-2134
27. 531884 Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL, Batra VK, Affrime MB BR J CLIN PHARMACOL 2002 54 3 309-319
28. 531885 Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B AM J CARDIOL 2002 90 10 1084-1091
29. 531888 Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Kosoglou T, Meyer I, Musiol B, Mellars L, Statkevich P, Miller MF, Soni PP, Affrime MB ATHEROSCLEROSIS 2000 151 1 Abs P135
30. 532825 Merck; Analysis of 2008 brightens long-term growth, but prospects below average. Scala S, Sanderson I, Cacciatore K, Perreault J SG COWEN SECURITIES CORPORATION 2004 February 19
31. 532826 Merck & Co; Publishing revised 2004, 2005 estimates. Krensavage M, Bailey M RAYMOND JAMES & ASSOCIATES INC 2004 January 29
32. 533335 Pfizer; reaffirms strong 2004 EPS growth; new product engine prepares to kick into gear. Kulju K, Schott C, Dimitrova T CREDIT SUISSE FIRST BOSTON 2004 January 22
33. 533472 Pfizer Inc; strengthening top-line story. Rubin J, Yu N, Garcia-Tunon C MORGAN STANLEY 2004 January 23
34. 534421 Merck announces first-quarter 2004 earnings per share EPS of 73 cents. Merck & Co Inc PRESS RELEASE 2004 April 22
35. 542578 Ezetimibe in hypercholesterolemia. Farnier M INT J CLIN PRACT 2002 56 8 611-614
36. 542601 Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Jeu L, Cheng JW CLIN THER 2003 25 9 2352-2387
37. 542618 Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Gagné C, Gaudet D, Bruckert E CIRCULATION 2002 105 21 2469-2475
38. 542632 Pharmacotherapy for dyslipidaemia - current therapies and future agents. Bays H, Stein EA EXP OPIN PHARMACOTHER 2003 4 11 1901-1938
39. 549661 Details of the SHARP study of heart and renal protection. COMPANY WORLD WIDE WEB SITE 2004 July 19
40. 550689 FDA Approves Vytorin ezetimibe/simvastatin, the first and only product to deliver powerful LDL cholesterol reduction through dual inhibition of the two sources of cholesterol in one tablet. Merck & Co Inc PRESS RELEASE 2004 July 23
41. 550701 MRK: Solid clean quarter - bring on Vytorin! Anderson T, Biegelsen L, Tooley JF PRUDENTIAL EQUITY GROUP INC 2004 July 22 1-8
42. 550964 Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J AM J CARDIOL 2004 93 12 1487-1494
43. 550968 C-reactive protein is reduced during ezetimibe coadministration with simvastatin in patients with primary hypercholesterolaemia. Sager P, Melani L, Lipka L, Strony J, Suresh R, Veltri E EUR HEART J 2003 24 Suppl 690
44. 550969 Efficacy and safety of ezetimibe co-administered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Goldberg AC, Sapre A, Liu J, Capece R, Capece YB MAYO CLIN PROC 2004 79 5 620-629
45. 550974 Ezetimibe/simvastatin therapy is more effective than simvastatin alone at reducing remnant-like particle cholesterol. Bays HE, Ose L, Fraser N, Quinto KL, Reyes R, Sapre A, Tribble D, Donahue SR J AM COLL CARDIOL 2004 43 Abs P481
46. 551092 Ezetimibe. Bays H EXPERT OPIN INVESTIG DRUGS 2004 11 11 1587-1604
47. 551111 New drugs for the treatment of hypercholesterolaemia. Iglesias P, Diez JJ EXPERT OPIN INVESTIG DRUGS 2004 12 11 1777-1789
48. 551113 Hypolipidemic therapy and cholesterol absorption. Manhas A, Farmer JA CURR ATHEROSCLEROSIS REP 2004 6 2 89-93
49. 551114 Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M AM J CARDIOL 2002 90 9 942-946
50. 551115 Associations between change in C-reactive protein and serum lipids during statin treatment. Strandberg TE, Vanhanen H, Tikkanen MJ ANN MED 2000 32 8 579-583
51. 551208 Ezetimibe: A viewpoint by Harold Bays. Bays H AM J CARDIOVASC DRUGS 2004 3 1 77-78
52. 551211 Effects of fibrates on metabolism of statins in human hepatocytes. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH DRUG METAB DISPOS 2004 30 11 1280-1287
53. 551216 Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Chang JT, Staffa JA, Parks M, Green L PHARMACOEPIDEMIOL DRUG SAF 2004 13 7 417-426
54. 551225 Market model update: Statin rebound helping PFE, although growth remains low in other areas. Henry SR, Molloy JM OPPENHEIMER 2004 June 21
55. 551227 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ CIRCULATION 2004 110 2 227-239
56. 551240 Efficacy of ezetimibe co-adminstered with simvastatin versus atorvastatin in patients with hypercholesterolemia. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J J AM COLL CARDIOL 2004 43 5 Suppl 115A
57. 551762 Effect of simvastatin (MK-733) on plasma triacylglycerol levels in rats. Sato A, Watanabe K, Fukuzumi H, Hase K, Ishida F, Kamei T BIOCHEM PHARMACOL 1991 41 8 1163-1172
58. 551763 Effect of simvastatin (MK-733) on sterol and bile acid excretion in rabbits. Ishida F, Iizuka Y, Kakubari K, Kurahashi Y, Sawasaki Y, Kamei T JPN J PHARMACOL 1990 51 3 35-45
59. 551770 Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL AM J MED 1999 87 4A S28-S38
60. 554534 Healthcare Weekly. Anderson TM, Faulkner RC, Shove DH, Sonnier JS PRUDENTIAL EQUITY GROUP INC 2004 1-60